Recently Viewed
Clear All$0.01
$0.00
(-26.28%)
As on 06-Sep-2022 15:49EDT
Today’s Range
52 Week Range
Liquidity
Market cap
--
Revenue (TTM)
--
Net Profit (TTM)
--
ROE
--
ROCE
--
P/E Ratio
--
P/B Ratio
--
Industry P/E
--
EV/EBITDA
--
Div. Yield
--
Debt to Equity
--
Book Value
--
EPS
--
Face value
--
Shares outstanding
--
CFO
$--
EBITDA
$--
Net Profit
$--
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Clarus Therapeutics Holdings Inc (CRXTW)
| -96.5 | -83.7 | -89.4 | -98.6 | -- | -- | -- |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Clarus Therapeutics Holdings, Inc. operates as a men's health specialty pharmaceutical company that focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral... formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for product to treat androgen-dependent inflammatory breast disease and certain forms of breast cancer. Clarus Therapeutics Holdings, Inc. was founded in 2003 and is based in Northbrook, Illinois. Read more
Founder, Pres, CEO & Director
Dr. Robert E. Dudley Ph.D.
Founder, Pres, CEO & Director
Dr. Robert E. Dudley Ph.D.
Headquarters
Northbrook, IL
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Clarus Therapeutics Holdings Inc (CRXTW) is $0.01 (NASDAQ) as of 06-Sep-2022 15:49 EDT. Clarus Therapeutics Holdings Inc (CRXTW) has given a return of -98.57% in the last 1 years.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2021
|
-50.18
|
-128.03
|
|
2020
|
--
|
--
|
|
2021
|
-50.18
|
-128.03
|
|
2020
|
--
|
--
|
The 52-week high and low of Clarus Therapeutics Holdings Inc (CRXTW) are Rs -- and Rs -- as of 04-Apr-2026.
Clarus Therapeutics Holdings Inc (CRXTW) has a market capitalisation of -- as on 06-Sep-2022. As per SEBI classification, it is a company.
Before investing in Clarus Therapeutics Holdings Inc (CRXTW), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.